MESO Stock Analysis: Buy, Sell, or Hold?
MESO - Mesoblast Limited American Depositary Shares
$15.43
-0.07 (-0.45%)
▼
5d:
+12.14%
30d:
+3.0%
90d:
+10.06%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 27, 2026
Get Alerted When MESO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MESO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: MESO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MESO is currently trading at $15.43, which is considered extended relative to its 30-day fair value range of $14.01 to $15.08. From a valuation perspective, the stock is trading at a discount (Forward PE: -221.4) compared to its historical average (206.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MESO is in a downtrend. The price is approaching resistance at $15.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MESO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.00 (+125.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MESO is in a downtrend. The price is approaching resistance at $15.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MESO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.00 (+125.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$14.01 -
$15.08
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 125.8% below Wall St target ($35.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$14.01 -
$15.08
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.68
Resistance Level
$15.66
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-221.43
Wall Street Target
$35.00
(+125.8%)
Revenue Growth (YoY)
1526.8%
Profit Margin
-144.3%
PE vs Historical
-221.4 vs 206.7
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 3:31 PM ET
Data refreshes hourly during market hours. Next update: 4:31 PM
Data refreshes hourly during market hours. Next update: 4:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MESO showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gregory George
BUY
2324072 shares
2026-04-10
Gregory George
BUY
1586890 shares
2026-04-09
Gregory George
BUY
1981890 shares
2026-04-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
